These results demonstrated that ARPC1B is significantly correlated with PDAC stemness, and the ARPC1B‐enriched high‐stemness subgroup exhibits a high frequency of driver gene mutations and increased intra‐tumour heterogeneity, which may explain the resistance to gemcitabine. This evidence concerns the gene ARPC1B and neoplasm.